| Name | Danicopan |
|---|
| Description | Danicopan, a selective and orally active small-molecule factor D inhibitor, inhibits alternative pathway of complement (APC) activity. Danicopan has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)[1]. |
|---|---|
| Related Catalog | |
| Target |
Factor D[1] |
| References |
| Molecular Formula | C26H23BrFN7O3 |
|---|---|
| Molecular Weight | 580.41 |